Nature Communications (Mar 2019)
PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
- Julia Weber,
- Jorge de la Rosa,
- Carolyn S. Grove,
- Markus Schick,
- Lena Rad,
- Olga Baranov,
- Alexander Strong,
- Anja Pfaus,
- Mathias J. Friedrich,
- Thomas Engleitner,
- Robert Lersch,
- Rupert Öllinger,
- Michael Grau,
- Irene Gonzalez Menendez,
- Manuela Martella,
- Ursula Kohlhofer,
- Ruby Banerjee,
- Maria A. Turchaninova,
- Anna Scherger,
- Gary J. Hoffman,
- Julia Hess,
- Laura B. Kuhn,
- Tim Ammon,
- Johnny Kim,
- Günter Schneider,
- Kristian Unger,
- Ursula Zimber-Strobl,
- Mathias Heikenwälder,
- Marc Schmidt-Supprian,
- Fengtang Yang,
- Dieter Saur,
- Pentao Liu,
- Katja Steiger,
- Dmitriy M. Chudakov,
- Georg Lenz,
- Leticia Quintanilla-Martinez,
- Ulrich Keller,
- George S. Vassiliou,
- Juan Cadiñanos,
- Allan Bradley,
- Roland Rad
Affiliations
- Julia Weber
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Jorge de la Rosa
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Carolyn S. Grove
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Markus Schick
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München
- Lena Rad
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Olga Baranov
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Alexander Strong
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Anja Pfaus
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Mathias J. Friedrich
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Thomas Engleitner
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Robert Lersch
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Rupert Öllinger
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- Michael Grau
- Department of Medicine A, University Hospital Münster
- Irene Gonzalez Menendez
- Institute of Pathology and Comprehensive Cancer Center, Eberhard Karls Universität Tübingen
- Manuela Martella
- Institute of Pathology and Comprehensive Cancer Center, Eberhard Karls Universität Tübingen
- Ursula Kohlhofer
- Institute of Pathology and Comprehensive Cancer Center, Eberhard Karls Universität Tübingen
- Ruby Banerjee
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Maria A. Turchaninova
- Laboratory of Genomics of Antitumor Adaptive Immunity, Privolzhsky Research Medical University
- Anna Scherger
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München
- Gary J. Hoffman
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Julia Hess
- Helmholtz Zentrum München, Research Unit Radiation Cytogenetics
- Laura B. Kuhn
- Helmholtz Zentrum München, Research Unit Gene Vectors
- Tim Ammon
- Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München
- Johnny Kim
- Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research
- Günter Schneider
- Department of Medicine II, Klinikum rechts der Isar, Technische Universität München
- Kristian Unger
- Helmholtz Zentrum München, Research Unit Radiation Cytogenetics
- Ursula Zimber-Strobl
- Helmholtz Zentrum München, Research Unit Gene Vectors
- Mathias Heikenwälder
- Divison of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ)
- Marc Schmidt-Supprian
- Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München
- Fengtang Yang
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Dieter Saur
- Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München
- Pentao Liu
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Katja Steiger
- Comparative Experimental Pathology, Technische Universität München
- Dmitriy M. Chudakov
- Laboratory of Genomics of Antitumor Adaptive Immunity, Privolzhsky Research Medical University
- Georg Lenz
- Department of Medicine A, University Hospital Münster
- Leticia Quintanilla-Martinez
- Institute of Pathology and Comprehensive Cancer Center, Eberhard Karls Universität Tübingen
- Ulrich Keller
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München
- George S. Vassiliou
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Juan Cadiñanos
- Instituto de Medicina Oncológica y Molecular de Asturias (IMOMA)
- Allan Bradley
- The Wellcome Trust Sanger Institute, Genome Campus, Hinxton
- Roland Rad
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München
- DOI
- https://doi.org/10.1038/s41467-019-09180-3
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 16
Abstract
Identification of cancer genes altered by non-genetic mechanisms in B-cell lymphoma is challenging. Here, the authors report the development of transposon tools to perform genome-wide recessive screens in vivo and validate identified putative tumor suppressor genes using a CRISPR/Cas9 validation platform.
